Active	Status	Sponsor type	Region	Phase	Filter
17 Active 14 Inactive 31 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Elewski, Boni E
NCT04227288: A Study Evaluating the Efficacy and Tolerability of Enstilar Foam in Patients With Nail Psoriasis	Completed	4	6	US	Enstilar Foam, calcipotriene and betamethasone dipropionate	University of Alabama at Birmingham, LEO Pharma	Nail Psoriasis	10/23	10/23
NCT06240351: A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA)	Recruiting	4	15	US	Baricitinib 4 MG Oral Tablet, Olumiant	University of Alabama at Birmingham, Eli Lilly and Company	Frontal Fibrosing Alopecia	04/25	12/25
TAK-279-PsO-3003, NCT06550076: A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis	Recruiting	3	1300	Europe, Canada, Japan, US, RoW	TAK-279	Takeda	Plaque Psoriasis	05/26	05/26
Woodard, Stefanie
NCT04340180: Evaluating the Performance of AI in Evaluating Breast MRI Performed With Dose Reduction	Active, not recruiting	1	20	US	Standard of Care (SOC) gadolinium Breast MRI, reduced 1/4 dose gadolinium Breast MRI with Artificial Intelligence (AI) to aid in evaluation.	University of Alabama at Birmingham, Bracco Corporate	Breast Benign Tumor, Breast Malignant Tumor	09/24	09/24
Yusuf, Nabiha
No trials found
Yalniz, Ceren
No trials found
Mooney, Quenteeria
No trials found